PYPD Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

4.420

Open

4.360

VWAP

4.38

Vol

54.26K

Mkt Cap

83.78M

Low

4.330

Amount

237.65K

EV/EBITDA(TTM)

--

Total Shares

19.08M

EV

71.83M

EV/OCF(TTM)

--

P/S(TTM)

--

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Show More

Events Timeline

(ET)

2026-03-17

08:50:00

PolyPid Granted FDA Waiver of $4.3M PDUFA Fee

2026-02-11 (ET)

2026-02-11

07:40:00

PolyPid CEO: 2026 Will Be a Transformative Year

2025-12-16 (ET)

2025-12-16

08:41:00

PolyPid Appoints Brooke Story as Chairman of the Board

2025-12-03 (ET)

2025-12-03

08:40:00

PolyPid Receives FDA Meeting Minutes Supporting NDA for D-PLEX100

2025-11-12 (ET)

2025-11-12

07:35:25

PolyPid anticipates sufficient cash reserves extending through 2026

2025-11-12

07:34:53

PolyPid Announces Q3 Earnings Per Share of 37 Cents, Below Consensus Estimate of 52 Cents

2025-09-16 (ET)

2025-09-16

08:41:43

PolyPid Finishes GMP Inspection by Israeli Ministry of Health

News

Newsfilter

03-31Newsfilter

PolyPid Submits NDA for D-PLEX₁₀₀ to Prevent Surgical Infections

Newsfilter

02-25Newsfilter

PolyPid to Participate in Upcoming Investor Conferences

seekingalpha

02-11seekingalpha

PolyPid Ltd. Q4 2025 Earnings Call Insights

seekingalpha

02-11seekingalpha

PolyPid Q4 Earnings Miss Expectations with GAAP EPS of -$0.41

Newsfilter

02-11Newsfilter

PolyPid Advances D-PLEX100 Commercialization Efforts

NASDAQ.COM

2025-12-16NASDAQ.COM

PolyPid Names Brooke Story as Board Chairman

3 Analyst Rating

Wall Street analysts forecast PYPD stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

9.00

Averages

11.00

High

13.00

Current: 0.000

Low

9.00

Averages

11.00

High

13.00

Roth Capital

Buy

downgrade

$10 -> $9

AI Analysis

2025-11-13

Reason

Roth Capital

Price Target

$10 -> $9

AI Analysis

2025-11-13

downgrade

Buy

Reason

Roth Capital lowered the firm's price target on PolyPid to $9 from $10 and keeps a Buy rating on the shares following the Q3 report. The firm expects a positive pre-new drug application meeting and a potential filing submission in the first half of 2026 for PolyPid. Given that D-PLEX100 "enjoys multiple designations" from the FDA, it should get a six-month review, the analyst tells investors in a research note.

Roth Capital

Buy

maintain

$9 -> $10

2025-08-14

Reason

Roth Capital

Price Target

$9 -> $10

2025-08-14

maintain

Buy

Reason

Roth Capital raised the firm's price target on PolyPid to $10 from $9 and keeps a Buy rating on the shares after meeting with its management following the company's Q2 results. The firm expects a fairly uneventful pre-NDA meeting given solid D-PLEX100 clinical data, which Roth believes is poised to transform the treatment paradigm in SSI associated with colorectal cancer surgery, providing benefits to patients and healthcare systems, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PYPD

Unlock Now

Valuation Metrics

The current forward P/E ratio for PolyPid Ltd (PYPD.O) is 0.00, compared to its 5-year average forward P/E of -1.78. For a more detailed relative valuation and DCF analysis to assess PolyPid Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.78

Current PE

0.00

Overvalued PE

-0.61

Undervalued PE

-2.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.62

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.29

Undervalued EV/EBITDA

-1.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

47.15

Current PS

3.58

Overvalued PS

244.58

Undervalued PS

-150.28

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

tell me a stock ticker that is a buy now

Intellectia · 24 candidates

Analyst Consensus: Strong BuyPe Ttm: <= 20Target Price Upside Potential: MoreAbovePriceMonth Price Change Pct: >= $15.00Annual Eps Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

Adtalem Global Education Inc

4.42B

Ardelyx Inc

1.94B

Oculis Holding AG

1.51B

Day One Biopharmaceuticals Inc

1.24B

Annexon Inc

1.02B

CytomX Therapeutics Inc

896.31M

penny stocks to buy tomorrow

Intellectia · 20 candidates

Market Cap: <= 1000.00MPrice: <= $5.00Relative Vol: >= 1.50Earnings Surprise: EpsBeatWeek Price Change Pct: >= $3.00

Ticker

Name

Market Cap$

Lexicon Pharmaceuticals Inc

566.90M

Summit Hotel Properties Inc

526.61M

Acacia Research Corp

385.84M

Auna SA

364.88M

GoldMining Inc

344.04M

Tigo Energy Inc

243.42M

Whales Holding PYPD

Trading Trends

People Also Watch

Frequently Asked Questions

What is PolyPid Ltd (PYPD) stock price today?

The current price of PYPD is 4.39 USD — it has increased 0

What is PolyPid Ltd (PYPD)'s business?

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

What is the price predicton of PYPD Stock?

Wall Street analysts forecast PYPD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYPD is11.00 USD with a low forecast of 9.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is PolyPid Ltd (PYPD)'s revenue for the last quarter?

PolyPid Ltd revenue for the last quarter amounts to -8.53M USD, increased 3.76

What is PolyPid Ltd (PYPD)'s earnings per share (EPS) for the last quarter?

PolyPid Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does PolyPid Ltd (PYPD). have?

PolyPid Ltd (PYPD) has 69 emplpoyees as of April 04 2026.

What is PolyPid Ltd (PYPD) market cap?

Today PYPD has the market capitalization of 83.78M USD.